Stonebranch Acquires HONICO to Strengthen Leadership in SAP Automation
10.9.2025 08:00:00 CEST | Business Wire | Press Release
Stonebranch, a leading provider of service orchestration and automation platforms (SOAP), today announced the acquisition of HONICO Systems, a recognized pioneer in SAP automation. This strategic move unites Stonebranch with HONICO’s SAP-native technology to deliver the most comprehensive, hybrid-ready SAP automation solution available today.
HONICO is best known for its flagship solution, BatchMan, an advanced workload automation platform purpose-built for SAP landscapes. BatchMan enables organizations to manage complex SAP jobs with ease, delivering improved visibility, control, and automation across mission-critical SAP business processes.
“This acquisition marks a significant milestone for Stonebranch as we continue to expand our leadership in the SOAP market,” said Stonebranch CEO Giuseppe Damiani. “HONICO’s unparalleled expertise in SAP automation complements our vision of delivering end-to-end orchestration across all enterprise systems. Together, we’re providing our customers with even greater control, visibility, and efficiency in automating their most critical business processes—whether in SAP, cloud-native applications, or legacy systems.”
A Strategic Step Toward Unified Enterprise Automation
Stonebranch intends to integrate HONICO’s powerful SAP automation solutions directly into its industry-leading Stonebranch Universal Automation Center (UAC) platform. The combined offerings will empower organizations to orchestrate and automate workloads across hybrid IT environments, including SAP systems, cloud platforms, and on-premises infrastructure. In addition, BatchMan will continue to be offered as a standalone solution.
Today’s enterprise customers increasingly demand automation solutions that seamlessly orchestrate both SAP and non-SAP environments. Organizations are under pressure to break down silos of automation, ensuring that business processes flow efficiently across disparate platforms without manual intervention. Combined, Stonebranch and HONICO directly address that market need, enabling enterprises to achieve true end-to-end orchestration, transfer data seamlessly, streamline operations, and accelerate digital transformation initiatives.
Building an SAP Automation Powerhouse
Stonebranch and HONICO bring an impressive portfolio of SAP certifications, validating their deep expertise and technical alignment with SAP technologies. They hold SAP Certified Integrations with SAP S/4HANA® and RISE with SAP S/4HANA® Cloud and are certified by SAP as an ABAP add-on for SAP NetWeaver®, ensuring seamless integration with the latest SAP environments and legacy systems alike.
Together, these certifications form the cornerstone of an SAP automation powerhouse. By combining certified solutions and proven technical integrations, enterprises are empowered to seamlessly orchestrate and automate jobs across SAP’s product ecosystem, spanning ERP, Business Technology Platform (BTP), industry-specific applications, data solutions, and more.
“Stonebranch provides what others merely claim: true hybrid IT automation that’s SAP intelligent by design, not by workaround,” said Damiani. “We’re not retrofitting old tools for modern needs—we’re setting a new bar for what SAP orchestration should be.”
This combined strength ensures organizations can automate SAP workloads with precision while eliminating silos and delivering cohesive enterprise-wide orchestration.
Enhanced Benefits for Customers of Both Organizations
The acquisition creates immediate value for both Stonebranch and HONICO customers. Stonebranch clients benefit from additional deep integration with SAP platforms, while HONICO customers gain access to Stonebranch’s expansive library of integrations across on-premises, cloud, and container solutions.
“We’re excited to join forces with Stonebranch, a company that shares our passion for innovation and automation excellence,” said HONICO CEO Claus-Uwe Hodum. “By combining our strengths with Stonebranch, we can offer our customers a broader, more powerful set of solutions that accelerate digital transformation and improve operational efficiency across both SAP and non-SAP systems alike. Together, we’re breaking down the silos of automation and helping enterprises achieve seamless, unified orchestration.”
The terms of the transaction have not been disclosed. The transaction is expected to close subject to customary regulatory approvals.
About Stonebranch
Stonebranch builds IT automation solutions that transform business IT environments. The Stonebranch Universal Automation Center (UAC) enables organizations to automate, manage, and orchestrate workloads and data pipelines in real time across hybrid IT environments, from on-premises to cloud and containerized microservices. Learn more at www.stonebranch.com
About HONICO
HONICO Systems specializes in workload automation and business process integration for SAP environments. With its flagship product BatchMan, HONICO helps enterprises streamline and optimize complex SAP job scheduling and automation processes. Headquartered in Hamburg, Germany, HONICO serves a global customer base across multiple industries. Learn more at www.honico.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909911794/en/
Contacts
Media Contact:
Scott Davis
Chief Marketing Officer
Stonebranch
scott.davis@stonebranch.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom